June 29, 2020— A pair of researchers is calling on Congress to relax the limitations on 340B price discounts for orphan drugs at safety-net hospitals during the national response to the COVID-19 pandemic. In an opinion piece posted June 25 in Health Affairs, they note that many of the drugs being tested to treat or prevent COVID are considered orphan drugs – meaning they were … [Read more...]
Senate Hearing Next Week on Outrageous Prescription Drug Prices
December 5, 2017—The Senate Health, Education, Labor and Pensions (HELP) Committee is holding a Dec. 12 hearing on new National Academies of Sciences (NAS) findings on why medicines cost so much and recommendations on how to fix the problem. The NAS’s Nov. 30 report is drawing attention for calling on the federal government to negotiate drugs prices with manufacturers, deny … [Read more...]